BR-1018 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Hypercholesterolemia. According to GlobalData, Phase I drugs for Hypercholesterolemia have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BR-1018’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BR-1018 overview

BR-1018 is under development for treatment of essential hypertension and primary hypercholesterolemia. It is an incrementally modified drug. It is administered as tablet.

Boryung Pharmaceutical overview

Boryung Pharmaceutical (Boryung) is a pharmaceutical company. it It offers product portfolio include Kanarb, Dukarb, Tuvero, TODULA, BESTO, and gelfosM. The company develops and manufactures over the counter and prescription drugs for the treatment of cancer, infections, and gene therapy. Its Kanarb drug used to treat hypertension and Gelfos, an antacid for the treatment of hypergastric acidity, gastritis and gastric fullness. The company’s pipeline products include BR1006, BR1007, BR1008 for treating hypertension; BR2002, a drug used to treat lymphoma; and BR8003, a vaccine designed for the treatment of Hepatitis A. Boryung is headquartered in Seoul, South Korea.

For a complete picture of BR-1018’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.